Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes Journal Article


Authors: Wong, W.; Lowery, M. A.; Berger, M. F.; Kemel, Y.; Taylor, B.; Zehir, A.; Srinivasan, P.; Bandlamudi, C.; Chou, J.; Capanu, M.; Varghese, A.; Yu, K. H.; Iacobuzio-Donahue, C. A.; Shia, J.; Klimstra, D. S.; Jarnagin, W. R.; Stadler, Z. K.; O’Reilly, E. M.
Article Title: Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes
Abstract: Background: Ampullary carcinoma (AC) is a rare gastrointestinal cancer. Pathogenic germline alterations (PGAs) in BRCA2 and potentially targetable somatic alterations (SAs) in ERBB2 and ELF3 have been previously described in AC. Memorial Sloan Kettering Cancer Center has implemented an opt-in strategy for germline testing (GT) and somatic testing (ST) for patients with AC to further evaluate the spectrum of PGAs and SAs. Methods: Forty-five patients with pathologically confirmed AC prospectively consented with the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) test (410-468 genes). A subset of the cohort (23 of the 45 patients) also consented to GT with MSK-IMPACT (76-88 genes). Germline data for 21 of the remaining 22 patients who had not consented to GT were obtained in a de-identified fashion without clinical correlation. Clinicopathologic features, treatment histories, and survival data for consenting patients were collected and analyzed. Results: Pancreaticobiliary, intestinal, and mixed features of the 2 types were the primary pathologic subtypes of AC identified in this cohort. No difference in median overall survival was found between pathologic subtypes. Eight of 44 patients (18%) were identified as harboring pathogenic mutations in BRCA2, ATM, RAD50, and MUTYH. In addition, this study found a wide spectrum of SAs in genes such as KRAS, MDM2, ERBB2, ELF3, and PIK3CA. Two patients in the cohort underwent SA-targeted therapy, and 1 had a partial radiographic response. Conclusions: Mutations in multiple somatic and germline genes were identified in this cohort. Significantly, actionable targets were identified in the tumors, and broader testing for PGAs and SAs should be considered for all patients with AC. © 2019 American Cancer Society
Keywords: germline; mutations; somatic; ampullary; genomic
Journal Title: Cancer
Volume: 125
Issue: 9
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2019-05-01
Start Page: 1441
End Page: 1448
Language: English
DOI: 10.1002/cncr.31951
PROVIDER: scopus
PMCID: PMC6467723
PUBMED: 30620386
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joanne Fu-Lou Chou
    334 Chou
  2. Anna Mary Varghese
    146 Varghese
  3. Zsofia Kinga Stadler
    394 Stadler
  4. Marinela Capanu
    388 Capanu
  5. David S Klimstra
    978 Klimstra
  6. Jinru Shia
    720 Shia
  7. Maeve Aine Lowery
    133 Lowery
  8. Kenneth Ho-Ming Yu
    164 Yu
  9. William R Jarnagin
    908 Jarnagin
  10. Ahmet Zehir
    345 Zehir
  11. Eileen O'Reilly
    790 O'Reilly
  12. Michael Forman Berger
    769 Berger
  13. Barry Stephen Taylor
    238 Taylor
  14. Yelena Kemel
    105 Kemel
  15. Winston Wong
    29 Wong